# Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks

> **NCT06025695** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 2000 (actual)

## Conditions studied

- Gastroenteritis

## Interventions

- **COMBINATION_PRODUCT:** GSK's liquid oral live attenuated HRV
- **COMBINATION_PRODUCT:** PCV-free liquid formulation of GSK's oral live attenuated HRV

## Key facts

- **NCT ID:** NCT06025695
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-01
- **Primary completion:** 2024-05-28
- **Final completion:** 2024-10-23
- **Target enrollment:** 2000 (ACTUAL)
- **Last updated:** 2025-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06025695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06025695, "Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06025695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*